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Summary: We previously described a motif prediction of major histocompat-
ibility complex allele-specific peptides and an in vitro assay for actual mea-
surement of peptide binding to human leukocyte antigen HLA-A2.1 molecules.
Using this method we have identified candidate cytotoxic T lymphocyte (CTL)
epitopes derived from a non-self-protein (influenza matrix) and self-protein
(p53). We now show that results of binding assays performed over a range of
peptide concentrations indicate that distinct differences in HLA-A2.1 peptide
binding affinities exist between the influenza matrix and p53 protein. The re-
sults for the influenza matrix protein indicate that the peptide that shows the
highest binding affinity to HLA-A2.1 is identical to the known immunodomi-
nant peptide recognized by influenza virus-specific CTLs. The results for p53
indicate that one of the peptides with a low binding affinity is capable of
inducing specific CTL responses, but CTLs recognizing the highest affinity
binding peptides were not obtained. These findings are discussed in terms of
the distinct implications for induction of cellular immune responses directed
against peptides with different binding affinities for HLA-A2.1 of proteins that
constitute attractive targets for tumor immunotherapy. Key Words: p53—
Influenza virus—Cytotoxic T lymphocyte—Peptide major histocompatibility
complex affinity—Immuno(sub)dominance.
In addition to surgery, chemotherapy, and irradi-
ation, alternative therapy is needed for those cancer
patients whose prognoses have not been markedly
improved using standard treatment. A potential
nontoxic therapeutic method is the treatment of pa-
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tients with tumor-specific T cells and/or vaccination
with tumor-specific peptides capable of inducing
T-cell responses (1-3). A critical step toward this
goal is the identification of tumor-specific T-cell
epitopes (4). In the majority of human malignancies,
the p53 tumor suppressor gene product is overex-
pressed and/or mutated (5). Processing of overex-
pressed/mutated p53 in tumor cells may give rise to
cytotoxic T lymphocyte (CTL) epitopes that differ
in quantity or quality from the p53 epitopes found in
121
122 H. W. NUMANETAL.
normal cells. Therefore p53 might yield useful tu-
mor-specific target epitopes. Loss of function of the
p53 gene, an important step in carcinogenesis, is
mostly due to a missense mutation of one allele,
leading to stabilization and overexpression of p53
(6). Overexpression also occurs after binding of p53
to a cellular or viral protein, such as the SV-40 large
T antigen, adenovirus type 5 E1B, heat shock pro-
tein members, or MDM2 (6).
CTLs recognize peptides presented by major his-
tocompatibility complex (MHC) class I molecules
at the cell surface (7,8). Binding of peptides to a
specific MHC molecule is dependent on so-called
allele-specific peptide motifs (9-12). The human cell
line 174CEM.T2 (T2) is unable to present endoge-
nously synthesized peptides to CTLs because of a
homozygous deletion of the MHC class II region
located on chromosome 6 (13,14). The HLA-A2.I
molecules are the only human leukocyte antigen
molecules present at the cell surface of the T2 cell
line, and these molecules are empty or occupied by
peptides derived from the signal peptide domains of
normal cellular proteins (11,15,16). The level of sta-
ble HLA-A2.1 cell surface molecules can be in-
creased by exogenously adding an HLA-A2.1 bind-
ing peptide. We used the T2 cell line to identify
peptides of the influenza matrix protein (12) and the
p53 protein (17) that bind to HLA-A2.1 by measur-
ing HLA-A2.1 cell-surface expression.
This study reports an evaluation of the assump-
tion that peptides of non-self-proteins binding with
the highest affinity to an MHC molecule are the
peptides of choice to yield immunodominant CTL
epitopes. On the other hand, it is likely that T cells,
bearing receptors capable of recognizing the best
binding peptides derived from self-proteins, are
subject to negative selection in the thymus. It would
therefore be important to determine the immunoge-
nicity of peptides of a self-protein, such as p53, in
comparison with a non-self-protein, such as influ-
enza matrix protein, in relation to MHC class I
binding affinity (18,19). Influenza matrix could be
used as a model protein in our study because HLA-
A2.1-restricted CTLs recognizing an immunodom-
inant peptide (influenza matrix 58-66) of the influ-
enza matrix have been described (20,21). In this
study the 15 HLA-A2.1-binding influenza matrix
peptides and four wild-type p53 peptides were
tested with respect to their binding affinities for the
HLA-A2.1 molecule and their published (influenza




Peptides were synthesized by solid-phase strate-
gies on an automated multiple peptide synthesizer
(Abimed AMS 422) using Fmoc chemistry. The pu-
rity of the peptides was determined by reverse-
phase high performance liquid chromatography.
Peptides were dissolved in dimethyl sulfoxide
(DMSO) (final DMSO concentration 0.25%), di-
luted in 0.9% NaCl to a peptide concentration of 2
mg/ml, and stored at - 20°C. The T2 cell line, a gift
from Dr. P. Cresswell (Yale University, New Ha-
ven, CT, U.S.A.), was cultured in Iscove's modi-
fied Dulbecco's medium (IMDM) (Biochrom KG;
Seromed, Berlin, Germany) with 2 mM glutamine,
100 lU/ml penicillin, 100 (o.g/ml kanamycin and 10%
fetal calf serum (PCS) (Hyclone Laboratories Inc.,
Logan, UT, U.S.A.).
The T2 binding assay was performed as previ-
ously described (12). In short, washed T2 cells were
incubated overnight with peptide or 0.9% NaCl.
Peptides binding to the HLA-A2.1 molecule will
stabilize this molecule at the cell surface of the T2
cell line and therefore increase HLA-A2.1 cell-
surface expression. Cells were stained by indirect
immunofluorescence, with the anti-HLA-A2.1
monoclonal antibody BB7.2 as a first antibody and
goat-anti-mouse (GAM) fluorescein isothiocyanate
(FITC)-labeled F(ab')2 fragments as a second anti-
body, and measured on a FACScan flow cytometer
(Becton Dickinson, Franklin Lakes, NJ, U.S.A.).
The fluorescence ratio (FR) was calculated by the
formula mean fluorescence experimental sample/
mean fluorescence background.
Induction of CTL Responses
The induction of CTL responses has been previ-
ously described (17). In short, peptide-loaded and
mitomycin-C treated T2 cells were used as antigen-
presenting cells with HLA-A2.I-positive peripheral
blood lymphocytes of a healthy donor as responder
cells. Cells were cultured in RPMI medium (Gibco,
Paislan) containing glutamine, antibiotics, 15%
pooled human serum, and 40 jig/ml peptide. Re-
sponding cells were restimulated weekly with
feeder cells, Epstein-Barr virus-transformed B
cells, and peptide. From week 3 on, 1% leuco-
agglutinin (Pharmacia, Uppsala, Sweden) and hu-
man recombinant interleukin-2 (120 lU/ml; Euroce-
tus, Amsterdam, The Netherlands) were added.
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Cytotoxic specificity of responding cells against
peptide-sensitized target cells was tested in stan-
dard 4-h 51Cr-release assays.
RESULTS
T2 Binding Assay
Fifteen influenza matrix (IM) peptides and four
wild-type p53 peptides were tested (Table 1) at dif-
ferent concentrations to determine their binding af-
finities for HLA-A2.1. Influenza matrix peptides
IM (2-11), IM (2-12), IM (3-11), IM (58-66), and IM
(59-68) had the highest affinity for the HLA-A2.1
molecule (Table 2). Peptide IM (58-66), the known
immunodominant epitope of the influenza matrix,
appeared to be the peptide with highest affinity for
HLA-A2.1 (Table 2). Two p53 peptides, p53 (187-
197) and p53 (65-73), had a similar binding affinity
to the HLA-A2.1 molecule (Table 2). The p53 (264-
271) peptide is the third-best binding peptide (Ta-
ble 2).



















































































































































Binding of influenza malrix and p53 peptides at concentrations of 100,
50, 25, 12.5, 6.25, 3.1, and 1.6 ng/ml (final concentration in the test).
Dashes indicate HLA-A2.J at the cell surface was not up-regulated. The
peptides are ranked in order of binding affinity to HLA-A2.1.
Induction of CTL Responses
We have already been successful in generating
stable, peptide-specific CTL clones against the p53
TABLE 1. Influenza matrix peptides and p53 peptides
identified as peptides binding to HLA-A2.1
Seq. no.
























L L T E V E T Y V
L L T E V E T Y V L
VLMEWLKTRPI
P I L S P L T K G I
I LSPLTKGI
I L S P L T K G I L
GI LGFVFTL
GI LGFVFTLTV
I L G F V F T L T V
RMGAVTTEV




R M P E A A P P V
G L A P P Q H L I R V
LLGRNSFEV
The sequence numbers (seq. no.) of the first and last amino
acids are shown. The peptides are ranked according to first seq.
no. Peptides were selected using sequence analysis and in vilro
assay for identifying peptides capable of binding to HLA-A2.1
(12,17).
(264-271) peptide (17). Using the same protocol, we
induced p53 (264-271) peptide-specific HLA-A2.1-
restricted CTL lines. Against the other wild-type
p53 peptides, p53 (25-33), p53 (65-73), and p53
(187-197), only a weak specific response at week 7
of culture was observed (Table 3). FACScan anal-
ysis performed during week 11 showed that in three
of four CTL lines, the majority of responding cells
were CD4+ (data not shown). Only the CTL line
against the p53 (264-271) peptide appeared to be
CD8+ (>97% CD8\ data not shown).
DISCUSSION
In recent reviews the potential therapeutic value
of T-cell-mediated immune responses has been ap-
praised (1-3). In addition to identifying new tumor-
specific target antigens of choice for T-cell therapy,
it is also important to identify the immunogenic
epitopes within antigens. Although p53 is a self-
protein subject to the laws of immunological toler-
ance, overexpressed p53 might serve as a tumor-
specific antigen. Targeting overexpressed p53 could
lead to therapy of the many types of cancer in which
p53 is involved.
Processing of p53 could be altered in cancer cells
compared with normal cells, stemming from, for ex-
ample, a much longer half-life of p53 (22). Tumor
cells may then end up displaying other p53 peptides
J Immunolher, Vol. 14, No. 2. 1993
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T2 was used as the target cell line in the 51Cr release assays, sp refers to the percentage of specific
lysis in the 5lCr release assay (T2 loaded with the specific peptide), asp refers to the percentage of
aspecific lysis in the 51Cr release assay (T2 loaded with an aspecific HLA-A2.1-binding peptide). E/T
is the effector/target ratio. On week 7 a split-well assay was performed with an unknown E/T ratio.
L
or different quantities of the same p53 peptides
compared with normal cells, allowing selective pre-
sentation at the cell surface and recognition by
CTLs. For presentation by MHC class II, mutation
in the staphylococcal nuclease protein enhanced the
processing and/or presentation of T-cell epitopes
(23), even though it is not directly involved in T-cell
epitope recognition. A similar mechanism of en-
hanced processing might operate for mutant p53 in
the case of MHC class I.
Members of the heat shock protein (HSP) family
selectively bind peptides and thereby influence an-
tigen processing and presentation (24). This may
occur in the case of p53 and MHC class I presen-
tation, because p53 can form complexes with HSP
(6). We suggest that processing of altered p53 com-
plexes could give rise to new CTL epitopes. In the
case of a self-protein such as p53, it is likely that
tolerance will play a role in determining the fre-
quency of specific CTLs recognizing (dominant)
self-epitopes in the postthymic environment. The
interactions involved in negative selection of devel-
oping T cells are probably the same as in clonal
activation of mature T cells in the periphery; a
threshold quantity of peptide/MHC complexes is
recognized by a given T cell receptor (TCR) (25).
CTL precursors capable of recognizing self-
peptides that are not processed or presented at sub-
threshold levels are therefore likely to be spared
negative selection.
An example of this process is found in a murine
system in which CTLs were obtained against pep-
tide determinants derived from several ubiquitous
or tissue-restricted self-proteins, e.g., fJ2-micro-
globulin, hemoglobin, and liver proteins (26). In the
case of the cytochrome-c molecule, it was shown
that not all possible MHC binding peptides are pro-
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cessed and presented at the cell surface (27). A so-
called cryptic self-peptide was capable of breaking
T-cell tolerance to other sites in the whole self-
protein (27). The same is true in murine models of
experimental allergic encephalomyelitis (EAE) (28).
In response to both cytochrome-c and myelin basic
protein in EAE, normally silent T cells are aroused.
From these studies it can be inferred that these po-
tentially self-reactive T cells are quiescent in vivo,
possibly because the epitope recognized by these T
cells is not processed at all or only at a very low
level. Alternatively, the epitopes are presented in a
nonphysiological manner, or the specific TCR-
bearing T cells may be anergic (26-28). One of the
possibilities explaining our finding of CTLs against
an autologous peptide is that we may have over-
come clonal anergy by high-concentration peptide
presentation on the antigen-presenting T2 cells.
The p53 (264-271) peptide is not the peptide with
highest affinity for HLA-A2.1 (Table 2). Yet the p53
(264-271) peptide so far is the only determinant
against which strong CTLs have reproducibly been
obtained. Comparison of the p53 peptide-binding
results with the peptide binding data obtained with
the influenza matrix peptides leads to the tentative
conclusion that the p53 (264-271) peptide is a sec-
ond-echelon peptide with respect to binding affin-
ity. Stable CTLs capable of recognizing either of
the two best binding peptides have not been ob-
tained despite repeated efforts of the type that con-
sistently yield p53- (264-271) specific CTLs. Our
failure to obtain CTLs capable of recognizing the
p53 peptide possessing the highest MHC binding
affinity may reflect the greater chance of inducing
tolerance against the immunodominant self-peptide.
The fact that the same protocol consistently yielded
specific CTLs when a p53 peptide of lesser binding
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affinity was used also supports the view that bind-
ing affinity may influence immunodominance. It is
important to know which of these p53 peptides are
processed and presented at the cell surface in a
complex with a HLA-A2.1 molecule.
Tolerance is thought to be induced against pep-
tides with the optimal binding affinity present at
threshold quantity on thymic or postthymic educa-
tor cells (19,25,29). By ignoring those peptides with
a level of presentation below this threshold, the im-
mune system can preserve the largest possible TCR
repertoire. Hence, autoreactive CTLs against the
most immunodominant self-peptides per MHC al-
lele have a greater chance of inducing tolerance.
According to Ohno (29), there seems to be a general
need (e.g., by HLA-A2.1) to ignore every high-
affinity self- or non-self-peptide, thus following the
safe course by suspecting all high-affinity peptides
as possible self-peptides. CTL epitopes of non-self-
proteins, in this view, could be peptides that are
endowed with suboptimal binding affinity to a given
class 1 MHC molecule (29).
It is predicted on a theoretical basis that peptide
IM (3-11) should be the best binder and therefore be
ignored by HLA-A2. t-restricted CTLs (29). Ac-
cording to this theory, the peptide IM (58-66) rec-
ognized by the HLA-A2.1-restricted CTLs should
be among the second-echelon MHC class I binding
peptides in terms of binding affinity. However, our
results show that the IM (58-66) peptide is the pep-
tide with the highest affinity for HLA-A2.1 (Table
2). This finding supports our view that the best
binding peptide of a non-self-protein is most likely
the immunodominant CTL epitope. We have ob-
tained similar data from various viral systems (ad-
enovirus/Sendai virus) in mice (unpublished obser-
vations).
We are now testing whether CTL responses di-
rected against influenza virus-infected targets can
be induced against other HLA-A2.1—binding influ-
enza matrix peptides and, if so, whether these
CTLs can lyse virus-infected cells or cells express-
ing matrix protein. This testing would address the
question of whether CTLs against the lower-
affinity-binding peptides of matrix protein can be
obtained and can lyse infected cells. The answer
would be relevant for the response against a self-
protein in which the best binding peptides might
have induced tolerance and the second-echelon
binding peptides are the most likely candidates to
arouse T-cell responses against.
In conclusion, the best MHC-binding peptides of
a self-protein possibly have induced tolerance.
Lower-affinity MHC-binding peptides of self-
proteins can induce CTLs, whereas the peptides
with the highest binding affinity of non-self-proteins
harbor the immunodominant CTL epitopes.
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